REGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium
July 06 2017 - 04:05PM
REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy based on its proprietary NAV® Technology
Platform, today announced that it will participate in the Piper
Jaffray GenomeRx Symposium on Tuesday, July 11, 2017 at the Lotte
New York Palace Hotel. REGENXBIO senior management will participate
in the following gene therapy panels:
- Next Gen Advancements: Delivery, Promoters, Vectors and More,
9:30-10:05 a.m. ET
- Tackling Manufacturing, 11:20-11:55 a.m. ET
- The Eye, 12:40-1:15 p.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO’s NAV® Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
CONTACT:
Investors
Heather Savelle, 617-340-6072
heather@argotpartners.com
Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Feb 2024 to Mar 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2023 to Mar 2024